Clinical Trials Directory

Trials / Completed

CompletedNCT04471220

Exercise Capacity Under Various FiO2 and Oxygen Flow Rates Using HFNC

Examination of Exercise Capacity Under Various Oxygen Concentrations and Oxygen Flow Rates Using High Flow Nasal Cannula

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
50 (actual)
Sponsor
National Hospital Organization Minami Kyoto Hospital · Academic / Other
Sex
All
Age
20 Years – 90 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to compare the exercise capacity (6-min walking distance) under the following 4 conditions using High-flow nasal cannula (HFNC); 1. FIO2 value that the minimum SpO2 value in a 6-minute walking test (6MWT) is 86-88%, and a flow of 10 L/min 2. FIO2 value that the minimum SpO2 value in a 6MWT is 86-88%, and a flow of 40-50 L/min 3. FIO2 value that the minimum SpO2 value in a 6MWT is 92-94%, and a flow of 10 L/min 4. FIO2 value that the minimum SpO2 value in a 6MWT is 92-94%, and a flow of 40-50 L/min

Detailed description

In the pervious study, the investigators demonstrated that 4 weeks of training using both high FIO2 and high flow through an HFNC significantly improved the 6MWD compared with training using a 6 L/min nasal cannula. However, it was unclear whether the effects of pulmonary rehabilitation under HFNC were due to high FIO2, high flow rate, or a synergistic effect. It is also unknown whether there are differences in the effects of pulmonary rehabilitation under HFNC for each underlying disease.

Conditions

Interventions

TypeNameDescription
DEVICEHigh-flow nasal cannulaThe nasal high flow therapy has enabled high flow oxygen to be derived through nasal cannula. This mode not only allows constant FiO2 during peak inspiratory flow but also confers benefits including a low level of continuous positive airway pressure with increased end-expiratory lung volume and reduced work of breathing, partly through intrinsic positive end-expiration pressure compensation and dead space washout. The inspired gases are warmed and humidified, improving comfort and possibly reducing airway inflammation, leading to improved drainage of respiratory secretions.

Timeline

Start date
2020-07-01
Primary completion
2022-09-29
Completion
2022-09-29
First posted
2020-07-15
Last updated
2022-09-30

Locations

1 site across 1 country: Japan

Source: ClinicalTrials.gov record NCT04471220. Inclusion in this directory is not an endorsement.